hemophilia gene therapy (Somatix/Baxter)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namehemophilia gene therapy (Somatix/Baxter)
Drug Alias NameFactor VIII gene therapy (Baxter/Somatix)Factor IX gene therapy (Baxter/Somatix)
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy
Mechanisms of ActionCoagulation factor VIII stimulantsCoagulation factor IX stimulants
TargetsCoagulation factor VIIICoagulation factor IX
Therapy Area/IndicationsHemophilia BHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSomatix Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSomatix IncBaxter Healthcare Ltd
Active IndicationsN/A
Inactive IndicationsHemophilia BHemophilia A

Other Information

ATC CodeN/A
Related LinksN/A